Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tarafenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 19/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 19/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarafenacin SCHEMBL3751324 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| Tarafenacin SCHEMBL2278272 | 0.99 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| Tarafenacin SCHEMBL29352113 | 0.99 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| Tarafenacin SCHEMBL2278264 | 0.99 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL13812723 | 0.93 | CHRM3 (0.88) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL5006033 | 0.90 | CHRM1 (0.85) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL5006034 | 0.90 | CHRM1 (0.85) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL5006869 | 0.89 | CHRM2 (0.86) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL5006871 | 0.89 | CHRM2 (0.86) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL5006110 | 0.89 | CHRM2 (0.90) | CHRM3CHRM2CHRM1CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838534-B2 | Quinuclidine derivatives as M3 antagonists | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-11-23 | — | — | US | disclosed |
| EP-2080507-A1 | Pharmaceutical formulations comprising an anticholinergic drug | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080523-A1 | Compositions comprising an antimuscarinic and a long-acting beta-agonist | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080508-A1 | Dry powder formulation comprising an anticholinergic drug | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-07-22 | — | — | EP | disclosed |
| EP-2049533-A2 | QUINUCLIDINE DERIVATIVES AS M3 ANTAGONISTS | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-04-22 | — | — | EP | disclosed |
| US-20080039493-A1 | Quinuclidine derivatives as M3 antagonists | CHIESI FARMACEUTICI S.P.A. | 2008-02-14 | — | — | US | disclosed |
| WO-2008012290-A2 | QUINUCLIDINE DERIVATIVES AS M3 ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-01-31 | — | — | WO | disclosed |
| EP-1882691-A1 | Quinuclidine derivatives as M3 antagonists | CHIESI FARMACEUTICI S.p.A. (IT) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039493-A1 | Quinuclidine derivatives as M3 antagonists | CHRM4, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 4/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.